Personalized Vaccine Shows Promise in Halving Return Risk for High-Risk Melanoma Patients
Health •
A trial indicates that an experimental mRNA vaccine, combined with immunotherapy, could significantly reduce the recurrence of deadly skin cancer.
Health News
Personalized Vaccine Shows Promise in Halving Melanoma Recurrence Risk
Health •
A new mRNA-based vaccine, combined with an existing immunotherapy drug, significantly reduced the risk of deadly skin cancer returning in high-risk patients during a late-stage trial.
New Personalized Vaccine Shows Promise in Preventing Melanoma Recurrence
Health •
An mRNA vaccine, administered alongside immunotherapy, demonstrated a meaningful improvement over existing treatments in a Phase 3 trial for high-risk melanoma patients.
Ab Roller Machine Emerges as a Popular Core Workout Tool
Health •
Users report effectiveness and an engaging workout experience with the affordable ab roller.
Céline Dion Reveals 17-Year Battle With Stiff-Person Syndrome Symptoms
Health •
The iconic singer details the debilitating and often unpredictable muscle spasms that affected her life for nearly two decades before her 2022 diagnosis.
Chronic Kidney Disease: A Silent Killer Affecting Millions
Health •
Often symptomless, chronic kidney disease contributes to tens of thousands of deaths annually and is linked to heart disease and stroke.
The Silent Kidney Disease Killing Thousands and How to Detect It
Health •
Chronic kidney disease, a condition often without symptoms, contributes to more deaths annually than breast and prostate cancer combined, yet remains largely unrecognized.
Salmonella Outbreak Linked to Imported Eggs Affects Hundreds
Health •
Public health officials are investigating an outbreak of Salmonella infections that has sickened hundreds of people, with imported eggs identified as a potential source.
Merck and Moderna Cancer Vaccine Shows Significant Promise in Melanoma Trial
Health •
An experimental mRNA vaccine combined with Keytruda reduced the risk of melanoma returning or death by 49% in a Phase 3 trial.